Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,421 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MG Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ashwagandha Extract (Capsule KSM-66 300 mg) on Sexual Health in Healthy Women

NCT05831241
View directory record Official record
Conditions
Sexual Health
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

NCT00974441
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 7, 2026, 1:54 AM EDT
Terminated Phase 3 Interventional Results available

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
View directory record Official record
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 18 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

NCT03828084
View directory record Official record
Conditions
Healthy
Interventions
Decitabine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

NCT01247285
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Hydrochloride, PROZAC WEEKLY®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 7, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

NCT00227318
View directory record Official record
Conditions
Hypertension
Interventions
ATACAND
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
42
States / cities
Mobile, Alabama • Long Beach, California • Redondo Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

NCT03657810
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 5 mg, Norco, Placebo
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain

NCT03566979
View directory record Official record
Conditions
Post-operative Dental Pain
Interventions
Test naproxen sodium tablet, Commercial naproxen sodium tablet, Commercial naproxen sodium liquid gels capsule, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

NCT06190561
View directory record Official record
Conditions
Healthy
Interventions
PF-07940367
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Results available

Relative Bioavailability of Pimasertib in Cancer Patients

NCT01992874
View directory record Official record
Conditions
Neoplasms
Interventions
Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 7, 2026, 1:54 AM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

NCT01157949
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

NCT00659750
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Encinitas, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 7, 2026, 1:54 AM EDT
Recruiting Phase 4 Interventional

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

NCT05444582
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel 52 MG Intrauterine System
Drug
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 7, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 7, 2026, 1:54 AM EDT